Access to the Enormous Chinese Medical Device Market
Annual Sales of medical devices are expected to increase at a rapid 16% CAGR reaching $100 billion USD in 2020, up from $53 billion USD in 2016.
Global Intellectual Property Rights and Vigorous Defense and Enforcement
TechBank Medical is missiondriven to establish superior patent positions in the Chinese market and vigorously defend these rights, while respecting the rights of enabling North American and European patents in order to create a portfolio of highly protective global IP rights.
We Lead Clinical Trials in China with Faster Enrollment and Lower Cost Relative to the US
Our extensive network of hospitals & KOLs greatly enhances collaboration during clinical trials. China’s large patient population provides an abundant pool of candidates for clinical trials, with the costs of clinical trials approximately 1/5th of U.S. costs.
We are Structured for Rapid Technology Commercialization
TechBank Medical is fully-equipped with a proprietary investment fund, an inhouse R&D team, a R&D center, and GMP manufacturing facilities.
Hospitals and Universities
US hospitals and universities working with TechBank Medical can experience a faster commercialization process and reduce the time to market. The final products’ availability in the global market will maximize the value of the innovations.
TechBank Medical has experience working with US hospitals and universities to rapidly translate leading innovations into the clinical settings faster than the traditional US start-up/spin-out model, resulting in a faster time to market and increased product sales.
Medical Device Companies
Established and start-up medical device companies collaborating with TechBank Medical provides will see an active partner willing to secure and defend patent protection within the Chinese market. Product development work with TechBank covers the spectrum from prototype development, to clinical trials, and large-scale manufacturing support. Additionally, the final products benefit from an immediate entry into the fastest-growing medical device market.
1. U.S. institutions provide a summary of medical technologies available for licensing in the Chinese market, executing NDAs first.
2. TechBank examines interesting technologies and provides feedbacks based on Chinese KOLs’ opinions.
3. U.S. institutions provide more details on selected technologies, with NDAs executed appropriately.
4. TechBank performs due diligence on the technologies.
5. US institutions and TechBank negotiate licensing terms.
6. TechBank lined up top-tier hospitals and KOLs and sets up new companies in China.
7. TechBank makes the initial investment in the project companies and leads future funding efforts.
8. The Startup companies begin the commercialization in China, which includes further development by Chinese doctors, clinical trials, CFDA approvals, and manufacturing and distribution.